Chen JJ, Nelson MV, Swope DM. Parkinson Disease. In: DiPiro JT, Talbert RL, Yee GC, et al (eds). Pharmacotherapy: A Pathophysiologic Approach. McGraw Hill, 7th edition (in press).
Lee KC, Chen JJ. Selegeline transdermal in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment (in press).
Panisset M, Schwid S, Ondo W, Fitzer-Attas C, Chen JJ. Safety of concomitant therapy with rasagiline and antidepressants in Parkinson’s disease. Mov Disord 2007;223(suppl 16):S104-S105.
Chen JJ, Fernandez HH. Community and long-term care management of Parkinson’s disease in the elderly: focus on MAO-B inhibitors. Drugs Aging 2007;24:663-680.
Chen JJ. Management of Depression and Anxiety. In: Pahwa R, Lyons KM (eds). Handbook of Parkinson’s Disease. New York: Informa Healthcare, 4th edition, 2007.
Fernandez HH, Chen JJ. Monoamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol 2007;30:150-168.
Swope DM, Chen JJ. Effectiveness and tolerability of pregabalin for dystonia and other hyperkinetic movement disorders: An open-label exploratory study. Mov Disord 2006;21(suppl 15):S385-S386.
Chen JJ, and Shimomura SK. Parkinsonism. In: Helms RA, Quan DJ, (eds). The Textbook of Therapeutics: Drug and Disease Management. Baltimore: Williams & Wilkins, 8th edition, 2006:1646-70.
Chen JJ, Swope DM. A case of complex movement disorder induced by fluoxetine with management of dystonia by botulinum toxin type A. J Clin Psychiatry 2005;66:267-268.
Chen JJ, Obering C. Apomorphine in the management of motor fluctuations associated with Parkinson’s disease. Clin Ther 2005;27;1710-24.
Chen JJ, Swope D. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 2005;45:878-94.
